Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Bial-Portela, Eisai deal

Eisai received exclusive rights to market Bial-Portela's Zebinix eslicarbazepine acetate ( BIA 2-093) in

Read the full 145 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE